GLP-1 and Muscle Loss: The Complete Guide (2026)

GLP-1 medications like Ozempic/Wegovy (semaglutide) and Mounjaro/Zepbound (tirzepatide) cause real muscle loss, but not because they attack muscle directly. Research suggests roughly 25-40% of the total weight you lose on these drugs can come from lean mass rather than fat, with the exact share depending heavily on your protein intake, your training, and how fast you lose. The good news: that ratio is something you can change.

This guide pulls together what the trials actually show, why muscle loss happens, how to tell fat loss from muscle loss, and the three levers proven to protect your muscle while the fat comes off.

How much muscle do you actually lose on a GLP-1?

When you lose weight on any GLP-1, the scale drops fast, and a portion of that drop is lean body mass. "Lean body mass" is everything in your body that is not fat: skeletal muscle, but also water, organs, and connective tissue. That distinction matters, because the often-quoted "~40% muscle loss" figure is really 40% lean mass, and not all of it is the muscle you care about.

Here is what the DXA-based trial data suggests. DXA (dual-energy X-ray absorptiometry) is the imaging scan researchers use to separate fat mass from lean mass.

• In SUSTAIN 8, a 52-week semaglutide trial, participants lost about 3.4 kg of fat mass and 2.3 kg of lean mass, meaning roughly 40% of the weight lost was lean.
• In the STEP 1 DXA analysis, 68 weeks of semaglutide produced about 15% total weight loss, with lean body mass falling about 9.7% in absolute terms. Critically, the proportion of the body that was lean actually rose by around 3 points, so participants became relatively leaner even as absolute lean mass fell.
• In the SURMOUNT-1 DXA substudy, 72 weeks of tirzepatide produced about 21.3% weight loss, with fat mass down about 34% and lean mass down about 11%, meaning only roughly 25% of the weight lost was lean (about 75% fat).

Put together, research suggests roughly 25-40% of the weight lost on GLP-1 medications can come from lean mass, with tirzepatide trials at the lower end and some semaglutide trials near 40%. For a deeper breakdown of the semaglutide numbers specifically, see how much muscle you lose on Ozempic and Wegovy.

One nuance worth holding onto: in nearly every trial, absolute lean mass falls but the lean-to-fat ratio improves. Your body gets relatively leaner. The concern is not that GLP-1s make you fatter; it is that aggressive, fast weight loss without protein and training pushes the lean-mass share toward the high end of that range.

Why "lean mass" overstates the muscle problem

It is worth slowing down on the difference between lean mass and skeletal muscle, because the two get conflated constantly and the confusion fuels a lot of fear. When a DXA scan reports lean mass, it is measuring everything that is not fat or bone: skeletal muscle, yes, but also body water, glycogen, and organ tissue. A meaningful chunk of the early lean-mass drop on a GLP-1 is water and glycogen leaving as your diet and carbohydrate intake shrink, not contractile muscle disappearing.

So when you read "40% of weight lost was lean," the share that is true, functional, strength-producing muscle is lower than that headline implies. This is why functional measures, like the handgrip improvements seen in the SEMALEAN cohort, matter as much as the DXA number. A falling lean-mass figure paired with rising strength is a very different story from a falling lean-mass figure paired with falling strength. The first is mostly water and a leaner body; the second is the scenario you actually want to prevent.

Drug-by-drug lean-mass comparison

The table below summarizes the reported lean-mass share by medication, the trial it comes from, and the levers shown to shift the ratio toward fat loss. Figures are population averages from controlled trials; your personal numbers depend on protein, training, and rate of loss.

Medication (brand / generic)	Reported lean-mass share of weight lost	Trial source	Preservation levers
Ozempic / Wegovy (semaglutide)	~40% (lean mass, not all skeletal muscle)	SUSTAIN 8 (DOM 2020); STEP 1 DXA analysis	Protein ~1.2-1.6 g/kg, resistance training 2-4x/week
Mounjaro / Zepbound (tirzepatide)	~25% (about 75% fat)	SURMOUNT-1 DXA substudy (DOM 2025)	Same levers; muscle quality preserved in SURPASS-3 MRI
Semaglutide (real-world cohort)	Lean -3.0 kg then stable; grip strength rose	SEMALEAN cohort (2025)	Suggests function can hold or improve over time

In the SURPASS-3 MRI substudy of tirzepatide, fat-free muscle volume fell about 5.5% to 6.9%, but muscle fat infiltration actually improved, meaning the remaining muscle looked metabolically healthier. And in the real-world SEMALEAN cohort, lean mass dropped about 3 kg early then stabilized, the share of participants with sarcopenic obesity fell from 49% to 33% over a year, and handgrip strength rose by roughly 4 kg. That last point is important: it is hard to square "the drug wastes muscle" with people getting measurably stronger.

Why do GLP-1 drugs cause muscle loss?

The mechanism is mostly indirect, and understanding it is what makes muscle loss preventable. GLP-1 drugs are powerful appetite suppressants. Trials show caloric intake dropping by roughly 16-39%, and when you eat less overall, you almost always eat less protein. Protein is the raw material and the signal your body uses to maintain muscle, so when it falls inside a calorie deficit, the body has both less to build with and less reason to hold what it has.

Layer on a few secondary factors: rapid weight loss itself burns more lean tissue than slow loss, fatigue and GI side effects can cut your activity, and early satiety makes protein-dense meals physically hard to finish. The result is a classic catabolic setup, the same one that happens in any aggressive diet, just easier to fall into because the appetite suppression is so effective.

What the evidence does not support is the idea that GLP-1s "attack" or directly waste muscle. A direct catabolic effect on human muscle has not been established, and some preclinical data even hints these drugs may be muscle-protective. The functional gains in SEMALEAN are consistent with that. For the full mechanism, read why GLP-1 drugs cause muscle loss.

The takeaway is empowering: because the cause is a protein deficit plus a missing training signal, both of those are things you can directly fix.

Does the rate of weight loss matter?

Yes, and it is one of the more controllable parts of the equation. The faster you lose weight, the higher the proportion that tends to come from lean tissue, because your body has less time to adapt and you are usually running a deeper deficit. Very fast loss also tends to coincide with the lowest food intake, which means the lowest protein intake, compounding the problem.

This does not mean you should aim to lose slowly for its own sake. It means that if your weight is dropping unusually fast and your protein is low and you are not training, you have stacked three risk factors at once. Easing the rate of loss, often by eating a little more (especially protein) on the days appetite allows, can meaningfully shift the fat-to-muscle ratio of what you lose. The dosing week itself shapes when those higher-appetite days fall, which we cover in the GLP-1 dose week and PK curve explained.

Why does losing muscle matter?

Muscle is not just aesthetic. It is metabolically active tissue, burning roughly 13 kcal per kg per day at rest versus about 4.5 kcal per kg per day for fat, so losing muscle quietly lowers your maintenance calories. (The popular "1 lb of muscle burns 50 calories a day" claim is an overestimate; the real number is more modest, but the direction is right.)

There are two bigger reasons to care. First, low muscle and strength, the hallmark of sarcopenia, are linked to falls, functional decline, insulin resistance, and higher mortality, a concern that grows for adults over 60. Second, muscle is your insurance against weight regain. The STEP 1 extension found that about two-thirds of lost weight was regained within a year of stopping semaglutide, and a lower resting metabolic rate from lost muscle plausibly speeds that rebound. Preserving muscle now makes maintaining your results later far more achievable, which is the whole point of keeping muscle after stopping a GLP-1.

How do you tell fat loss from muscle loss?

You cannot, if all you watch is the scale. Both fat loss and muscle loss register as a lower number, so bodyweight alone is a useless signal for which tissue you are losing.

The clearest at-home warning sign is falling strength. If your lifts, your grip, or your stamina are sliding while the scale drops, that is muscle leaving. Other signs include persistent fatigue, feeling "soft" or "skinny fat" despite weight loss, slower recovery, and feeling cold. We cover the full list in 7 signs you are losing muscle on a GLP-1, and the how-to-tell breakdown in fat loss vs muscle loss on a GLP-1.

To move from "I feel weaker" to actual data, you need a body-composition method. This is exactly the gap Myo is built to close: instead of one ambiguous scale number, it trends your fat mass and lean mass separately, so "I lost 4 lb this month" becomes "I lost 3 lb of fat and held my muscle," which is the only version of that sentence that matters.

The three levers that preserve muscle

Across the research, the same three interventions show up again and again. None of them is exotic.

1. Eat enough protein

Protein is the single highest-leverage habit for keeping muscle in a deficit. The 2025 joint advisory from the OMA, TOS, ACLM, and ASN recommends roughly 1.2-1.6 g/kg per day during active weight loss, with a practical floor often cited around 80-120 g per day. The same advisory is blunt that protein alone is likely inadequate without resistance training.

The problem is hitting that target when a GLP-1 has killed your appetite. A 2025 study of GLP-1 users found that fewer than half (about 43%) reached even the 1.2 g/kg minimum. That is the core pain point, and we cover the exact targets in how much protein to eat on a GLP-1, plus practical tactics in how to hit your protein goal with no appetite and the best high-protein foods for GLP-1 users.

2. Lift weights 2-4 times a week

Resistance training is the signal that tells your body to defend its muscle in a deficit. A meta-analysis found that resistance training offset roughly 93% of the lean-mass loss caused by calorie restriction compared with dieting alone, while aerobic exercise on its own does a poor job of preserving muscle. For most people, 2-4 full-body sessions a week with progressive overload (gradually adding load or reps) is enough. See the full playbook in resistance training on a GLP-1.

3. Track body composition, not just weight

You cannot manage what you cannot see, and the scale hides the one number that matters. Tracking fat mass versus lean mass over time is the only way to confirm you are losing the right tissue. We compare every method, from DEXA to smart scales, in how to track muscle loss on a GLP-1, and review the best apps to track GLP-1 and muscle loss.

A useful supporting habit: creatine (about 3-5 g per day) is the best-evidenced supplement for supporting strength in a deficit, though it sits on top of protein and training rather than replacing them, as covered in creatine and supplements on a GLP-1.

Can you build muscle, or is the goal just to lose less?

For most people on a GLP-1, the realistic goal is not to bulk up but to recompose: hold (or slightly gain) muscle while losing fat. "Body recomposition" means the scale moves down because fat leaves, while lean mass stays roughly flat. Pure muscle gain usually favors a calorie surplus, which is the opposite of what GLP-1 weight loss is doing, so building a lot of new muscle in a deep deficit is hard.

That said, two groups consistently see real recomposition even while losing weight: beginners who have never trained seriously, and people returning to lifting after a long break. Their muscles respond strongly to the training stimulus, so they can add lean tissue while fat comes off. If that is you, the combination of protein plus resistance training can flip your trajectory from "losing muscle" to "rebuilding it," which is the best-case outcome of being on these drugs at all.

Is muscle loss on a GLP-1 permanent?

Generally, no. Muscle lost in a calorie deficit can usually be rebuilt, and it tends to come back faster than it was originally built thanks to "muscle memory." The window opens widest once your appetite returns, whether that is on a maintenance dose or after you taper off. With protein high and training consistent, the lean mass you shed earlier is recoverable for most people, though individual results vary and the more muscle you preserved in the first place, the easier the rebuild.

This is exactly why the preservation work matters most during the active weight-loss phase, and why it matters even more during the taper, the moment most people stop measuring. We cover that high-risk window in keeping your muscle after stopping a GLP-1.

How to put it together

If you take one thing from this guide, make it this: trial averages are population numbers, and your personal muscle-loss share is something you steer. Hit your protein, lift a few times a week, and measure body composition instead of just bodyweight, and you push your own ratio toward the fat-loss end of that 25-40% range.

That is the entire reason Myo exists in a muscle-first form. It keeps your fat-vs-muscle trend, your protein target, your resistance sessions, and your dose log in one place, so the "40% problem" stops being an invisible risk and becomes a set of numbers you can actually act on. The scale lies; your body composition, your protein count, and your strength trend tell the truth.

Whatever tools you use, the principle holds. GLP-1 muscle loss is real, it is mostly preventable, and the levers are protein, training, and measurement, none of which require a prescription.

References

• SUSTAIN 8 (Diabetes, Obesity and Metabolism, 2020)
• STEP 1 DXA analysis (Journal of the Endocrine Society)
• SURMOUNT-1 DXA substudy (DOM 2025)
• SEMALEAN real-world cohort (2025)
• Tirzepatide and lean mass review (2025)
• OMA/TOS/ACLM/ASN joint advisory (2025)
• Protein intake in GLP-1 users (Johnson et al., 2025)
• Resistance training and lean-mass preservation meta-analysis
• STEP 1 extension, weight regain after stopping (DOM 2022)
• Sarcopenia and GLP-1 review